Compare, Analyse Glenmark Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ACTAVIS (US) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ACTAVIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ACTAVIS
Dec-18
GLENMARK PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs71213,860-   
Low Rs4849,298-   
Sales per share (Unadj.) Rs349.63,399.9-  
Earnings per share (Unadj.) Rs32.8-1,095.1-  
Cash flow per share (Unadj.) Rs44.3358.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.614,023.2-  
Shares outstanding (eoy) m282.17332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.73.4 50.2%   
Avg P/E ratio x18.2-10.6 -172.4%  
P/CF ratio (eoy) x13.532.3 41.7%  
Price / Book Value ratio x3.00.8 364.3%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,6253,851,172 4.4%   
No. of employees `00012.016.9 71.2%   
Total wages/salary Rs m20,5610-   
Avg. sales/employee Rs Th8,196.066,912.6 12.2%   
Avg. wages/employee Rs Th1,708.10-   
Avg. net profit/employee Rs Th768.5-21,552.6 -3.6%   
INCOME DATA
Net Sales Rs m98,6551,130,823 8.7%  
Other income Rs m2,08121,625 9.6%   
Total revenues Rs m100,7361,152,448 8.7%   
Gross profit Rs m15,85829,633 53.5%  
Depreciation Rs m3,259483,402 0.7%   
Interest Rs m3,34665,255 5.1%   
Profit before tax Rs m11,335-497,399 -2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672126,857 1.3%   
Tax Rs m3,756-6,303 -59.6%   
Profit after tax Rs m9,250-364,239 -2.5%  
Gross profit margin %16.12.6 613.4%  
Effective tax rate %33.11.3 2,615.1%   
Net profit margin %9.4-32.2 -29.1%  
BALANCE SHEET DATA
Current assets Rs m66,968463,804 14.4%   
Current liabilities Rs m40,211410,297 9.8%   
Net working cap to sales %27.14.7 573.2%  
Current ratio x1.71.1 147.3%  
Inventory Days Days8320 425.5%  
Debtors Days Days8166 122.4%  
Net fixed assets Rs m33,322128,003 26.0%   
Share capital Rs m2820-   
"Free" reserves Rs m55,7700-   
Net worth Rs m56,0524,664,116 1.2%   
Long term debt Rs m35,7381,642,404 2.2%   
Total assets Rs m132,8887,291,074 1.8%  
Interest coverage x4.4-6.6 -66.3%   
Debt to equity ratio x0.60.4 181.1%  
Sales to assets ratio x0.70.2 478.7%   
Return on assets %9.5-4.1 -231.1%  
Return on equity %16.5-7.8 -211.3%  
Return on capital %17.8-4.8 -368.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m40,1400-   
CASH FLOW
From Operations Rs m13,242404,000 3.3%  
From Investments Rs m-6,990221,946 -3.1%  
From Financial Activity Rs m-7,387-693,386 1.1%  
Net Cashflow Rs m-2,971-67,103 4.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.63 Rs / USD

Compare GLENMARK PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: J.B.CHEMICALS  ELDER PHARMA  ALEMBIC PHARMA  GSK PHARMA  NOVARTIS  



Today's Market

Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)

Indian stock markets mostly remained in the negative zone during the week except for Wednesday.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks (Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years) (Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat Views On News (Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

Will Algo Traders Take Away All Your Profits? (Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

These Rebirth of India Stocks Are Raring to Compete with Tesla (The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Guide on How to Profit from Sensex 100,000.
7 Stocks to Ride the Coming Rebirth of India Rally. Full Details Here...
A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Revealed: Top 7 Stocks to Consider Buying Right Now...

GLENMARK PHARMA SHARE PRICE


Feb 20, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - NOVARTIS COMPARISON

COMPARE GLENMARK PHARMA WITH

OTHER USEFUL LINKS

MARKET STATS